Industry Welcomes the European Commission Commitment to a Sustainable and Competitive Off-Patent Biologics Market
|Data publikacji:||Rodzaj wiadomości: Komunikaty|
|Data dokumentu źródłowego:||Źródła: EFPIA, EGA|
Przejdź do źródła
Przejdź do drugiego źródła
The European pharmaceutical industry welcomes the initiative by the European Commission Directorate General for the Internal Market, Industry, Entrepreneurship and SMEs (DG Grow) to host on 6 October 2015, an event on access to biosimilar medicines in Europe. The “Workshop on Access to and Uptake of Biosimilar Medicinal Products” brings together healthcare stakeholders to share their perception, perspectives and experiences with biosimilar medicines developments, following the conclusion of the Process on Corporate Responsibility in the Pharmaceutical Sector, which ran from 2011 to 2014. In addition, IMS Health presented the preliminary results of a new report on ‘The impact of biosimilar competition”.